Demographic characteristics and risk factors for invasive fungal sinusitis in the context of COVID-19: A systematic review and meta-analysis

• Published in: International journal of infectious diseases Vol. 144; p. 107054
• Main Authors: Chen, Han, Yu, Longgang, Wang, Lin, Zhang, Jisheng, Yan, Xudong, Jiang, Yan
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.07.2024; Elsevier
• Subjects: COVID-19; COVID-19 - complications; COVID-19 - diagnosis; COVID-19 - epidemiology; Diabetes Mellitus - epidemiology; Female; Humans; Invasive Fungal Infections - diagnosis; Invasive Fungal Infections - drug therapy; Invasive Fungal Infections - epidemiology; Invasive fungal sinusitis; Male; Meta-analysis; Middle Aged; Risk Factors; SARS-CoV-2; Sinusitis - epidemiology; Sinusitis - microbiology; COVID-19; Invasive fungal sinusitis; Risk factors; Meta-analysis
• ISSN: 1201-9712; 1878-3511; 1878-3511
• DOI: 10.1016/j.ijid.2024.107054

•Invasive fungal sinusitis patients with COVID-19 had an average age of 53.72 years.•Invasive fungal sinusitis patients with COVID-19 were predominantly males.•The mean onset interval from COVID-19 to Invasive fungal sinusitis was 19.09 days.•The most common comorbidity among invasive fungal sinusitis patients was diabetes.•Diabetes, steroid administration, and COVID-19 PCR positivity were risk factors. To identify the demographic characteristics and potential risk factors of invasive fungal sinusitis (IFS) patients with Coronavirus Disease in 2019 (COVID-19). Web of Science, Embase, the Cochrane Library, and PubMed were searched from database inception to August 2023 using the combination of medical searching heading terms “invasive fungal sinusitis” and “COVID-19” and their free words. The research protocol was registered on PROSPERO (CRD42023467175). A total of 53 studies were included. The mean age of IFS patients with COVID-19 was 53.72 (95% credible interval [CI]: 51.08, 56.36), with 66% males (95% CI: 0.62, 0.70), and 81% diabetes (95% CI: 0.77, 0.86). The mean time from COVID-19 diagnosis to IFS onset was 19.09 days (95% CI: 16.96, 21.22). The percentage of patients with COVID-19 PCR positivity was 33% (95% CI: 0.21, 0.45). Overall, 71% of patients receiving steroid therapy during COVID-19 infection (95% CI: 0.63, 0.78). The odds ratio of diabetes mellitus, steroid administration, and COVID-19 PCR positivity were 6.09, 2.21, and 1.82, respectively. COVID-19 infection did not affect the IFS stage. IFS patients with COVID-19 had an average age of 53.72 years and were predominantly males, with a mean interval of 19.09 days from COVID-19 diagnosis to IFS onset. Diabetes, steroid administration, and COVID-19 PCR positivity were risk factors.